Attack on Academe

The Tax Reform Act of 1986 has become law. The deed is done, for universities and everyone and there seems little further point in arguing over probable effects. The question that remains is why, at a time when Congress is concerned about preserving the nation's economic competitiveness and technological leadership, did it choose to withdraw significant tax advantages from universities, institutions which, given the way American science is organized, are essential to these goals? The two most se

Written byThomas Head
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Tax Reform Act of 1986 has become law. The deed is done, for universities and everyone and there seems little further point in arguing over probable effects. The question that remains is why, at a time when Congress is concerned about preserving the nation's economic competitiveness and technological leadership, did it choose to withdraw significant tax advantages from universities, institutions which, given the way American science is organized, are essential to these goals?

The two most serious losses are certainly in the areas of the deductibility of charitable giving and the ability to issue tax-exempt bonds to finance capital costs of construction and renovation of research facilities. Private fund raising is the major tool that universities, public and private, have at their disposal to improve the quality of teaching and research without additional cost to their students or the taxpayers. The best economic models we have suggest that charitable ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies